Deutsche Bank Comments on Valeant Pharma (VRX) Following Q4 Call
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Valeant (VRX) PT Cut to $40 at Canaccord Genuity
March 16, 2016 9:40 AM EDTCanaccord Genuity analyst Neil Maruok reiterated a Hold rating and lowered his price target on Valeant Pharmaceuticals (NYSE: VRX) to $40.00 (from $75.00).
Maruok commented, "guidance was even lower than our base-case scenario and we believe has begun to erode investor confidence in Valeants underlying business. We believe that the implementation of the partnership with Walgreens,... More
Ackman Said to Add to Valeant Pharma (VRX) Stake - Chatter
March 15, 2016 3:58 PM EDTPershing Square's Bill Ackman is adding to his stake in Valeant Pharma (NYSE: VRX) amid today's sell-off, according to unconfirmed market chatter.... More
Ackman's Pershing Square Said to Support Valeant Pharma (VRX) CEO Pearson; Wants More Oversight - Bloomberg
March 15, 2016 3:24 PM EDTBill Ackman's Pershing Square said to support Valeant Pharma (NYSE: VRX) CEO Mike Pearson, according to Bloomberg. The firm is looking for more oversight of Valeant's finances, communications.
... MoreValeant Pharma (VRX) Bounces Modestly Off Lows Following Ackman Letter
March 15, 2016 12:23 PM EDTValeant Pharma (NYSE: VRX) is moving off the lows following the... More
Ackman's Pershing Square Sends Letter to Investors Following Valeant's (VRX) Q4 Report, Updated Outlook
March 15, 2016 12:15 PM EDTRegulatory News:
Pershing Square Holdings, Ltd. today released an email to investors. The text of the email is set forth below:
Dear Pershing Square Investor,
Today, Valeant (NYSE: VRX) reported preliminary unaudited earnings for Q4, updated guidance for Q1, full year 2016 and the next twelve months. In particular, management shocked the market with revenue and earnings... More
Valeant Pharma (VRX) Unable to Find Support; Shares Down 48%
March 15, 2016 12:07 PM EDTValeant Pharma (NYSE: VRX) takes another leg lower, nearing $36 or down 48%.
... MoreValeant Pharma (VRX) Results Suggest Disruption in the Business - Evecore ISI's Raffat
March 15, 2016 10:56 AM EDTEvercore ISI analyst, Umer Raffat, commented on Valeant Pharma (NYSE: VRX) after the call.
"I think it will be an understatement to say that this has clearly been a very humbling call for me," he said.
".. today's results suggests that while... More
Horizon Pharma (HZNP) Falls Amid Lower Outlook from Valeant
March 15, 2016 9:51 AM EDTHorizon Pharma (NASDAQ: HZNP) is seeing morning pressure following weak earnings and lower guidance from peer Valeant Pharma (NYSE: VRX). HZNP is down 7% while VRX is down 31.6%.
... MoreValeant Pharma (VRX) CEO said his best estimate is 10-K will be filed in April - Bloomberg
March 15, 2016 9:48 AM EDTValeant Pharma (NYSE: VRX) CEO said his best estimate is 10-K will be filed in April - Bloomberg
... MoreValeant Pharma (VRX) Corrects adj.-EBITDA Guidance Lower to ~$6B on Call
March 15, 2016 9:38 AM EDTValeant Pharma (NYSE: VRX) corrected EBITDA guidance for the next four quarters to about $6 billion on its earning call. An earlier release forecast next four quarters (second quarter 2016 first quarter 2017) guidance of about $6.2 - $6.6 billion.
Shares are lower by 36 percent.
... More